Size matters: a review of the challenges in and importance of multimodal approaches to the management of patients with small, node-negative, triple-negative breast cancer.

Given the small patient number, this finding did not reach statistical significance; however, these results suggest that the benefit from the addition of durvalumab to NACT could be independent of tumor size.

also in 111,027 other papers